Comparative Pharmacology
Head-to-head clinical analysis: ESTAZOLAM versus HALCION.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTAZOLAM versus HALCION.
ESTAZOLAM vs HALCION
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that binds to GABA-A receptors at the alpha-1 subunit, enhancing the effect of GABA by increasing chloride ion conductance, leading to neuronal hyperpolarization and CNS depression.
Triazolam is a benzodiazepine that enhances the effect of GABA at the GABA-A receptor, increasing chloride ion conductance and causing neuronal hyperpolarization, leading to CNS depression.
1-2 mg orally at bedtime.
0.25 mg orally once daily at bedtime, maximum 0.5 mg per day.
None Documented
None Documented
Terminal elimination half-life: 10-24 hours (mean ~17 hours); prolonged in elderly and hepatic impairment.
Clinical Note
moderateEstazolam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Estazolam is combined with Fluticasone propionate."
Clinical Note
moderateEstazolam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Estazolam."
Clinical Note
moderateEstazolam + Erythromycin
"The serum concentration of Erythromycin can be increased when it is combined with Estazolam."
Clinical Note
moderateEstazolam + Cyclosporine
Terminal elimination half-life is 1.5–5.5 hours (mean 2.5 hours). Short half-life minimizes next-day sedation.
Renal: ~90% as metabolites, <1% unchanged. Fecal: small amount, ~10%.
Primarily renal (80%) as conjugated metabolites; fecal (8%); unchanged drug <1%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Estazolam."